相关实验视频

Updated: Jul 21, 2025

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

凯素激酶2 (CK2):在急性髓性白血病中可能是治疗标

Øystein Bruserud^1,2, Håkon Reikvam^1,2

¹Institute for Clinical Science, Faculty of Medicine, University of Bergen, 5021 Bergen, Norway.

|July 29, 2023

概括

蛋白激酶CK2 (凯激酶2) 是急性髓性白血病 (AML) 的关键调节剂. 高CK2水平与生存率差相关,这表明CK2抑制是潜在的AML治疗策略.

科学领域:

生物化学生物化学
在瘤学瘤学.
分子生物学分子生物学

背景情况:

蛋白激酶CK2 (CK2) 是人类蛋白质组的一个主要贡献者.
CK2在调节癌细胞存活和扩散至关重要的细胞内信号通路方面发挥着至关重要的作用.
在急性髓性白血病 (AML) 中观察到升高的CK2水平,这是一种具有攻击性的骨髓恶性瘤.

研究的目的:

研究CK2在AML病变发生中的作用及其作为治疗点的潜力.
评估高CK2水平在AML患者的预后意义.
评估CK2抑制剂,特别是CX-4945/silmitasertib在AML中的临床前疗效.

主要方法:

关于AML中CK2功能的现有文献的审查.
分析CK2在关键信号通路 (PI3K-Akt,Jak-Stat,NFκB,Wnt,DNA修复) 中的作用.
对CX-4945/silmitasertib对人类初级AML细胞影响的临床前数据的评估.

主要成果:

诊断时AML细胞中高CK2水平与患者存活率降低和复发风险增加有关.
通过CX-4945/silmitasertib抑制CK2,在AML细胞中显示出抗增殖和前性作用.
虽然CX-4945/silmitasertib显示出有希望的结果,但临床AML研究缺乏,在其他癌症中注意到胃肠道和骨髓问题等毒性.

结论:

CK2是AML进展和化疗抵抗的重要因素.
高CK2水平可能作为AML的预后生物标志物,需要在多变量分析中进一步调查.
抑制CK2,特别是Silmitasertib,是AML的一个有希望的治疗途径,需要进一步的临床验证.

关键词:

在CK2中使用.急性骨髓性白血病 (AML) 是一种急性骨髓性白血病.灭症 (apoptosis) 是一种死亡的过程.化学电阻是一种化学电阻.化学疗法化疗化疗细胞因子细胞因子预后预后预后它们的扩散和扩散.这里是Silmitasertib.

更多相关视频

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Transducer Mechanism: Enzyme-Linked Receptors

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...